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Mature teratomaTeratomas are composed of elements of all three germ layers,
while all are capable of potentially undergoing malignant transforma-
tion, this remains a relatively rare phenomenon (Boughton et al.,
1987). The most common malignant transformation is squamous
cell carcinoma with malignant melanoma being the rarest. Only
three dozen cases have been reported in over 100 years (Xu et al.,
2011). Herein we report a case of malignant melanoma which arose
within a mature cystic teratoma.
A 64 year old woman presented with complaint of shortness of
breath. A CT demonstrated a right-sided pleural effusion, an ovarian
mass and ascites. On physical exam she was noted to have a large
left adnexal mass and an abdomen distended with ascites. Her CA125
was markedly elevated at 1256.9 U/ml. Based on a clinical suspicion of
an ovarian malignancy she underwent a laparotomy, hysterectomy,
bilateral salpingoophoretomy, omentectomy and resection of diffuse
tumoral implants. Intraoperatively she was noted to have multiple
tumor implants on the diaphragm, peritoneum, bowel, mesentery
and omentum, in addition to a 25 cm partially cystic and solid left
ovarian mass. She had 2.5 liters of ascites. At completion of surgery
she had no residual macroscopic tumor. Post-operatively she did
well and was discharged home on post-operative day #7.
Gross examination of the ovarian tumor specimen showed a
smooth outer surface and a multicystic inner surface with widespread
necrosis and hemorrhage. A single tooth was identiﬁed. On micro-
scopic examination, there was a malignant melanoma component
demonstrating a sheet-like growth pattern with moderate nuclear
pleomorphism, an increased nuclear to cytoplasmic ratio, nuclear
hyperchromatism,mitoticﬁgures, and the presence ofmelanin pigment⁎ Corresponding author at: Division of Gynecologic Oncology, Penn State Hershey
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Open access under CC BY-NC-ND license .(Fig. 1). On immunohistochemical analysis, the tumor cells were
strongly positive for S-100, vimentin and HMB-45, consistent with
malignant melanoma.
After conﬁrming that her melanoma was not metastatic from a
dermatologic lesion, the patientwas started on temozolamide (Temodar)
120 mg daily for 6 weeks. Her therapy was discontinued after cycle
number two secondary to thrombocytopenia. A CT of the chest/
abdomen/pelvis after cycle one and a PET/CT after discontinuation
of cycle number two, both showed no evidence of disease recurrence,
respectively.
Malignant melanoma arising within a mature cystic teratoma is
extremely rare, with an estimated incidence of 0.2 to 0.8% (Dasgupta
and Brasﬁeld, 1964). Since 1901, only 34 cases have been described.
The prognosis of women with primary ovarian malignant melanoma
is especially grim with limited effective chemotherapeutic agents,
however the addition of chemotherapy to surgery has resulted in
some long term survivors without evidence of disease (Xu et al., 2011).
Agents with anti-tumor activity include decarbazine and temozolomide,
however despite objective response rates, survival is less than 1 year
(Neyns et al., 2010). Recent studies have highlighted the efﬁcacy of
immunotherapy and targeted therapies in the treatment of malig-
nant melanoma (Hodi et al., 2008; Hodi et al., 2010) however, care
should be taken in extrapolating the responses seen with these
agents in cutaneous malignant melanomas to ovarian melanoma, as
each melanoma subtype has unique oncogenic pathways with vari-
ous mutations (Wong et al., 2005).Fig. 1. Malignant melanoma component of mature teratoma. The tumor cells show a
sheet-like pattern, nuclear pleomorphism, melanin pigment and mitotic ﬁgures.
(Hematoxylin-Eosin, 400× magniﬁcation).
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arising from a teratoma. Despite its rarity this entity should be recog-
nized for its aggressive clinical course and resultant poor prognosis.
Considering the limited efﬁcacy of current chemotherapies, future
studies are warranted investigating the role of biologic agents capa-
ble of inducing a directed, cytotoxic host immune response. Toward
that end, these rare cases should be studied in an attempt to identify
tumor-associated antigens capable of being targeted via immunotherapy.Conﬂict of interest statement
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